The global market for Tigecycline API was valued at US$ 1921 million in the year 2024 and is projected to reach a revised size of US$ 5683 million by 2031, growing at a CAGR of 17.0% during the forecast period.
Tigecycline (CAS锛�220620-09-7),is an tetracycline antibiotic medication for a number of bacterial infections.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tigecycline API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tigecycline API.
The Tigecycline API market size, estimations, and forecasts are provided in terms of output/shipments (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tigecycline API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tigecycline API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Sun Pharma
Teva
Transo-Pharm USA LLC
Rochem International Inc
NEWEDGE Overseas
Mac-Chem Products (India) Pvt.Ltd
Chongqing Fuan Pharmaceutical
WUHAN ZY PHARMACEUTICAL CO LTD
Melody Healthcare Pvt Ltd
Zhejiang Hisun Pharmaceutical
Olon S.p.A
HAORUI ENTERPRISES LIMITED
HANWAYS PHARMCHEM CO., LTD.
Sumar Biotech
by Type
Above 98 %
Above 99 %
by Application
Injection
Others
Production by Region
North America
Europe
China
India
Israel
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Tigecycline API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Tigecycline API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Tigecycline API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Tigecycline API 麻豆原创 Overview
1.1 Product Definition
1.2 Tigecycline API by Type
1.2.1 Global Tigecycline API 麻豆原创 Value Growth Rate Analysis by Type: 2024 VS 2031
1.2.2 Above 98 %
1.2.3 Above 99 %
1.3 Tigecycline API by Application
1.3.1 Global Tigecycline API 麻豆原创 Value Growth Rate Analysis by Application: 2024 VS 2031
1.3.2 Injection
1.3.3 Others
1.4 Global 麻豆原创 Growth Prospects
1.4.1 Global Tigecycline API Production Value Estimates and Forecasts (2020-2031)
1.4.2 Global Tigecycline API Production Capacity Estimates and Forecasts (2020-2031)
1.4.3 Global Tigecycline API Production Estimates and Forecasts (2020-2031)
1.4.4 Global Tigecycline API 麻豆原创 Average Price Estimates and Forecasts (2020-2031)
1.5 Assumptions and Limitations
2 麻豆原创 Competition by Manufacturers
2.1 Global Tigecycline API Production 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Tigecycline API Production Value 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Key Players of Tigecycline API, Industry Ranking, 2023 VS 2024
2.4 Global Tigecycline API 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.5 Global Tigecycline API Average Price by Manufacturers (2020-2025)
2.6 Global Key Manufacturers of Tigecycline API, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Tigecycline API, Product Offered and Application
2.8 Global Key Manufacturers of Tigecycline API, Date of Enter into This Industry
2.9 Tigecycline API 麻豆原创 Competitive Situation and Trends
2.9.1 Tigecycline API 麻豆原创 Concentration Rate
2.9.2 Global 5 and 10 Largest Tigecycline API Players 麻豆原创 Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Tigecycline API Production by Region
3.1 Global Tigecycline API Production Value Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.2 Global Tigecycline API Production Value by Region (2020-2031)
3.2.1 Global Tigecycline API Production Value by Region (2020-2025)
3.2.2 Global Forecasted Production Value of Tigecycline API by Region (2026-2031)
3.3 Global Tigecycline API Production Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.4 Global Tigecycline API Production Volume by Region (2020-2031)
3.4.1 Global Tigecycline API Production by Region (2020-2025)
3.4.2 Global Forecasted Production of Tigecycline API by Region (2026-2031)
3.5 Global Tigecycline API 麻豆原创 Price Analysis by Region (2020-2025)
3.6 Global Tigecycline API Production and Value, Year-over-Year Growth
3.6.1 North America Tigecycline API Production Value Estimates and Forecasts (2020-2031)
3.6.2 Europe Tigecycline API Production Value Estimates and Forecasts (2020-2031)
3.6.3 China Tigecycline API Production Value Estimates and Forecasts (2020-2031)
3.6.4 India Tigecycline API Production Value Estimates and Forecasts (2020-2031)
3.6.5 Israel Tigecycline API Production Value Estimates and Forecasts (2020-2031)
4 Tigecycline API Consumption by Region
4.1 Global Tigecycline API Consumption Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
4.2 Global Tigecycline API Consumption by Region (2020-2031)
4.2.1 Global Tigecycline API Consumption by Region (2020-2025)
4.2.2 Global Tigecycline API Forecasted Consumption by Region (2026-2031)
4.3 North America
4.3.1 North America Tigecycline API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.3.2 North America Tigecycline API Consumption by Country (2020-2031)
4.3.3 U.S.
4.3.4 Canada
4.4 Europe
4.4.1 Europe Tigecycline API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.4.2 Europe Tigecycline API Consumption by Country (2020-2031)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Tigecycline API Consumption Growth Rate by Region: 2020 VS 2024 VS 2031
4.5.2 Asia Pacific Tigecycline API Consumption by Region (2020-2031)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Tigecycline API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.6.2 Latin America, Middle East & Africa Tigecycline API Consumption by Country (2020-2031)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Tigecycline API Production by Type (2020-2031)
5.1.1 Global Tigecycline API Production by Type (2020-2025)
5.1.2 Global Tigecycline API Production by Type (2026-2031)
5.1.3 Global Tigecycline API Production 麻豆原创 Share by Type (2020-2031)
5.2 Global Tigecycline API Production Value by Type (2020-2031)
5.2.1 Global Tigecycline API Production Value by Type (2020-2025)
5.2.2 Global Tigecycline API Production Value by Type (2026-2031)
5.2.3 Global Tigecycline API Production Value 麻豆原创 Share by Type (2020-2031)
5.3 Global Tigecycline API Price by Type (2020-2031)
6 Segment by Application
6.1 Global Tigecycline API Production by Application (2020-2031)
6.1.1 Global Tigecycline API Production by Application (2020-2025)
6.1.2 Global Tigecycline API Production by Application (2026-2031)
6.1.3 Global Tigecycline API Production 麻豆原创 Share by Application (2020-2031)
6.2 Global Tigecycline API Production Value by Application (2020-2031)
6.2.1 Global Tigecycline API Production Value by Application (2020-2025)
6.2.2 Global Tigecycline API Production Value by Application (2026-2031)
6.2.3 Global Tigecycline API Production Value 麻豆原创 Share by Application (2020-2031)
6.3 Global Tigecycline API Price by Application (2020-2031)
7 Key Companies Profiled
7.1 Sun Pharma
7.1.1 Sun Pharma Tigecycline API Company Information
7.1.2 Sun Pharma Tigecycline API Product Portfolio
7.1.3 Sun Pharma Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.1.4 Sun Pharma Main Business and 麻豆原创s Served
7.1.5 Sun Pharma Recent Developments/Updates
7.2 Teva
7.2.1 Teva Tigecycline API Company Information
7.2.2 Teva Tigecycline API Product Portfolio
7.2.3 Teva Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.2.4 Teva Main Business and 麻豆原创s Served
7.2.5 Teva Recent Developments/Updates
7.3 Transo-Pharm USA LLC
7.3.1 Transo-Pharm USA LLC Tigecycline API Company Information
7.3.2 Transo-Pharm USA LLC Tigecycline API Product Portfolio
7.3.3 Transo-Pharm USA LLC Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.3.4 Transo-Pharm USA LLC Main Business and 麻豆原创s Served
7.3.5 Transo-Pharm USA LLC Recent Developments/Updates
7.4 Rochem International Inc
7.4.1 Rochem International Inc Tigecycline API Company Information
7.4.2 Rochem International Inc Tigecycline API Product Portfolio
7.4.3 Rochem International Inc Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.4.4 Rochem International Inc Main Business and 麻豆原创s Served
7.4.5 Rochem International Inc Recent Developments/Updates
7.5 NEWEDGE Overseas
7.5.1 NEWEDGE Overseas Tigecycline API Company Information
7.5.2 NEWEDGE Overseas Tigecycline API Product Portfolio
7.5.3 NEWEDGE Overseas Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.5.4 NEWEDGE Overseas Main Business and 麻豆原创s Served
7.5.5 NEWEDGE Overseas Recent Developments/Updates
7.6 Mac-Chem Products (India) Pvt.Ltd
7.6.1 Mac-Chem Products (India) Pvt.Ltd Tigecycline API Company Information
7.6.2 Mac-Chem Products (India) Pvt.Ltd Tigecycline API Product Portfolio
7.6.3 Mac-Chem Products (India) Pvt.Ltd Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.6.4 Mac-Chem Products (India) Pvt.Ltd Main Business and 麻豆原创s Served
7.6.5 Mac-Chem Products (India) Pvt.Ltd Recent Developments/Updates
7.7 Chongqing Fuan Pharmaceutical
7.7.1 Chongqing Fuan Pharmaceutical Tigecycline API Company Information
7.7.2 Chongqing Fuan Pharmaceutical Tigecycline API Product Portfolio
7.7.3 Chongqing Fuan Pharmaceutical Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.7.4 Chongqing Fuan Pharmaceutical Main Business and 麻豆原创s Served
7.7.5 Chongqing Fuan Pharmaceutical Recent Developments/Updates
7.8 WUHAN ZY PHARMACEUTICAL CO LTD
7.8.1 WUHAN ZY PHARMACEUTICAL CO LTD Tigecycline API Company Information
7.8.2 WUHAN ZY PHARMACEUTICAL CO LTD Tigecycline API Product Portfolio
7.8.3 WUHAN ZY PHARMACEUTICAL CO LTD Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.8.4 WUHAN ZY PHARMACEUTICAL CO LTD Main Business and 麻豆原创s Served
7.8.5 WUHAN ZY PHARMACEUTICAL CO LTD Recent Developments/Updates
7.9 Melody Healthcare Pvt Ltd
7.9.1 Melody Healthcare Pvt Ltd Tigecycline API Company Information
7.9.2 Melody Healthcare Pvt Ltd Tigecycline API Product Portfolio
7.9.3 Melody Healthcare Pvt Ltd Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.9.4 Melody Healthcare Pvt Ltd Main Business and 麻豆原创s Served
7.9.5 Melody Healthcare Pvt Ltd Recent Developments/Updates
7.10 Zhejiang Hisun Pharmaceutical
7.10.1 Zhejiang Hisun Pharmaceutical Tigecycline API Company Information
7.10.2 Zhejiang Hisun Pharmaceutical Tigecycline API Product Portfolio
7.10.3 Zhejiang Hisun Pharmaceutical Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.10.4 Zhejiang Hisun Pharmaceutical Main Business and 麻豆原创s Served
7.10.5 Zhejiang Hisun Pharmaceutical Recent Developments/Updates
7.11 Olon S.p.A
7.11.1 Olon S.p.A Tigecycline API Company Information
7.11.2 Olon S.p.A Tigecycline API Product Portfolio
7.11.3 Olon S.p.A Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.11.4 Olon S.p.A Main Business and 麻豆原创s Served
7.11.5 Olon S.p.A Recent Developments/Updates
7.12 HAORUI ENTERPRISES LIMITED
7.12.1 HAORUI ENTERPRISES LIMITED Tigecycline API Company Information
7.12.2 HAORUI ENTERPRISES LIMITED Tigecycline API Product Portfolio
7.12.3 HAORUI ENTERPRISES LIMITED Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.12.4 HAORUI ENTERPRISES LIMITED Main Business and 麻豆原创s Served
7.12.5 HAORUI ENTERPRISES LIMITED Recent Developments/Updates
7.13 HANWAYS PHARMCHEM CO., LTD.
7.13.1 HANWAYS PHARMCHEM CO., LTD. Tigecycline API Company Information
7.13.2 HANWAYS PHARMCHEM CO., LTD. Tigecycline API Product Portfolio
7.13.3 HANWAYS PHARMCHEM CO., LTD. Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.13.4 HANWAYS PHARMCHEM CO., LTD. Main Business and 麻豆原创s Served
7.13.5 HANWAYS PHARMCHEM CO., LTD. Recent Developments/Updates
7.14 Sumar Biotech
7.14.1 Sumar Biotech Tigecycline API Company Information
7.14.2 Sumar Biotech Tigecycline API Product Portfolio
7.14.3 Sumar Biotech Tigecycline API Production, Value, Price and Gross Margin (2020-2025)
7.14.4 Sumar Biotech Main Business and 麻豆原创s Served
7.14.5 Sumar Biotech Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Tigecycline API Industry Chain Analysis
8.2 Tigecycline API Raw Material Supply Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Tigecycline API Production Mode & Process Analysis
8.4 Tigecycline API Sales and 麻豆原创ing
8.4.1 Tigecycline API Sales Channels
8.4.2 Tigecycline API Distributors
8.5 Tigecycline API Customer Analysis
9 Tigecycline API 麻豆原创 Dynamics
9.1 Tigecycline API Industry Trends
9.2 Tigecycline API 麻豆原创 Drivers
9.3 Tigecycline API 麻豆原创 Challenges
9.4 Tigecycline API 麻豆原创 Restraints
10 Research Findings and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 麻豆原创 Size Estimation
11.1.3 麻豆原创 Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer
Sun Pharma
Teva
Transo-Pharm USA LLC
Rochem International Inc
NEWEDGE Overseas
Mac-Chem Products (India) Pvt.Ltd
Chongqing Fuan Pharmaceutical
WUHAN ZY PHARMACEUTICAL CO LTD
Melody Healthcare Pvt Ltd
Zhejiang Hisun Pharmaceutical
Olon S.p.A
HAORUI ENTERPRISES LIMITED
HANWAYS PHARMCHEM CO., LTD.
Sumar Biotech
听
听
*If Applicable.
